Previous 10 | Next 10 |
First Quarter 2020 Revenue $33.1 Million, a 42% Increase Compared to First Quarter 2019 Generated $5.6 Million in Cash from Operations during the First Quarter 2020 EWING, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company...
EWING, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its first quarter 2020 financial results and recent operating progress before the market opens on Tuesday, May 5, 2020. Management will host a webcast and conference cal...
Editor's note: Seeking Alpha is proud to welcome Andy Jones as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Antares Pharma ( ATRS ...
EWING, N.J., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 40 th Annual Health Care Conference on Wednesday March 4, 2020 at 11:20 am Eastern Time. ...
EWING, N.J., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter and full year 2019 financial results and recent operating progress before the market opens on Tuesday, March 3, 2020. Management will host a webcast an...
After decades of unprofitable operations, Antares Pharma ( ATRS ) achieved profitability in Q3 2019 with impressive revenue growth of 92.7% YOY. For Q3 ending September 30, the company reported revenue of $34.3 million and net income of $1.0 million. As noted in the table below, revenue has ...
Company Thesis Antares Pharma's ( ATRS ) flagship product XYOSTED administered as an injection for testosterone replacement therapy has seen monstrous growth with prescription volume breaking through the 10,000 units/mo. mark in December 2019. While the company is not profitable, its net los...
EWING, N.J., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (The Company) today announced 2020 full-year net revenue guidance of $135 to $155 million, which includes a range of potential revenue scenarios for AMAG’s Makena. In addition, the Company also a...
After a big run-up in its share price following better-than-expected earnings and guidance in November, Antares Pharma (NASDAQ: ATRS) shares are down 10% at 3:30 p.m. EDT on Thursday. The company didn't report any news, so today's drop could be a simple case of profit-taking following a...
(Sourced from Idorsia) On July 16th, 2019, I shared my initial Idorsia ( IDRSF ) article, " Idorsia: A Swiss Biotech Poised for Fantastic Growth ." At the time of publication, the stock ended the day trading for $23.70 and closed on December 6th, 2019, trading for the price of $30.89 a sha...
News, Short Squeeze, Breakout and More Instantly...
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma PR Newswire SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (" Halozyme ") today announced that the waiting period unde...
Antares Pharma Inc shares ( NASDAQ: ATRS ) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that...